UKRLOGOS Group
Published November 12, 2022 | Version v1
Book Open

Organization of diagnosis, surgical treatment and anesthetic support of secondary and tertiary hyperparathyroidism

Creators

  • 1. State Scientific Institution «Scientific and Practical Center of Preventive and Clinical Medicine» of the State Management of Affairs
  • 2. Bogomolets National Medical University

Contributors

Description

The monograph systematizes and describes modern approaches to the organization of medical care for patients with hyperparathyroidism against the background of chronic renal failure by a multidisciplinary team.

The monograph is intended for scientists, nephrologists, surgeons, anesthesiologists, endocrinologists, therapists, pathologists, and interns.

Files

Електронна монографія.pdf

Files (5.0 MB)

Name Size Download all
md5:5dad3aeeeb87889d9ea6d54c5379b84b
5.0 MB Preview Download

Additional details

References

  • Борисова В. И., Дубров С. А., Лянскорунский В. Н. Анестезиологическое обеспечение при травматологической операции у пациентки с терминальной стадией хронической почечной недостаточности находящейся на программном гемодиализе. Біль, знеболення та інтенсивна терапія. 2018. № 2. С. 95-104. https://doi.org/10.25284/2519-2078.2(83).2018.135827.
  • Денисенко А.И., Черний В.И., Ткаченко Р.П. Вопросы лечения вторичного гиперпаратиреоза глазами анестезиолога. Опыт периоперационного анестезиологического обеспечения и интенсивной терапии при паратиреоидном хирургическом вмешательстве. Клінічна та профілактична медицина. 2021. Т.2. № 16.С. 4-16. https://doi.org/10.31612/2616-4868.2(16).2021.01.
  • Черній В. І., Денисенко А.І. Концентрація кортизолу крові, гемодинаміка та метаболізм пацієнтів з вторинним гіперпаратиреозом, можливості периопераційної корекції. Біль, знеболення та інтенсивна терапія. 2021. № 3 (96). С. 54-63. https://doi.org/10.25284/2519-2078.3(96).2021.242148.
  • Черній В.І., Денисенко А.І. Сучасні можливості використання непрямої калориметрії у післяопераційному енергомоніторингу. Клінічна та профілактична медицина. 2020. Т2. № 12. С. 79-88. https://doi.org/10.31612/2616-4868.2(12).2020.05.
  • Черній В.І., Денисенко А.І. Сучасні можливості використання непрямої калориметрії у післяопераційному енергомоніторингу. Клінічна та профілактична медицина. 2020. Т2. № 12. С. 79-88. https://doi.org/10.31612/2616-4868.2(12).2020.05.
  • Aldrete J., Kroulik D. (1970). A post-anesthesia recovery score. Anesth. Analg., 49, (6), 924-934. PMID: 5534693.
  • Aldrete J., Kroulik D. A post-anesthesia recovery score. Anesth. Analg. 1970. Vol. 49 (6). P. 924-934. PMID: 5534693.
  • Andrade J. S., Mangussi-Gomes J. P, Rocha L. A. et al. Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy. Braz. J. Otorhinolaryngol. 2014. Vol. 80. P. 29–34. https://doi.org/10.5935/1808-8694.20140008.
  • Block G. A., Bushinsky D. A., Cunningham J. et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017. Vol. 317 (2). P. 146–155. https://doi.org/10.1001/jama.2016.19456.
  • Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin. Thromb. Hemost. 2004. Vol.30 (5). P. 579 – 589. https://doi.org/10.1055/s-2004-835678.
  • Bomback Andrew S., Ksbirsagar Abbijit V., Ferris Maria I. et al. Disordered aldosterone-volume relationship in end-stage kidney disease. Jornal of the Renin-Angiotensin-Aldosterone System. 2009. Vol. 10. (4). P. 229–237. https://doi.org/10.1177/1470320309352353.
  • Brandenburg V. M., Kramann R., Rothe H. et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol. Dial. Transplant. 2017. Vol. 32. P. 126–132. https://doi.org/10.1093/ndt/gfv438].
  • Bureo J. C, Arévalo J. C., Antón J., Adrados G., Jiménez Morales J. L., Robles N. R. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol. Nutr. 2015. Vol. 62. P. 300–305. https://doi.org/10.1016/j.endoen.2015.08.007.
  • Cai Q., Mukku V.K., Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr. Cardiol. Rev. 2013. Vol. 9 (4). P. 331–339. https//doi.org/10.2174/1573403X10666140214122234.
  • Chen H. H., Lin C. J., Wu C. J. et al. Chemical ablation of recurrent and persistent secondary hyperparathyroidism after subtotal parathyroidectomy. Ann. Surg. 2011. Vol. 253. P. 786–790. https://doi.org/10.1097/SLA.0b013e318211ccc2.
  • Chow T. L., Chan T. T., Ho Y. W., Lam S. H. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch. Surg. 2007. Vol. 142. P. 644–648. https://doi.org/10.1001/archsurg.142.7.644.
  • Chutia H., Ruram A. A., Bhattacharyya H., Boruah P., Nath C. Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease. J. Lab. Physicians. 2013. Vol. 5. P. 51–54. https://doi.org/10.4103/0974-2727.115935.
  • Corneci M., Stanescu B., Trifanescu R. et al. (2012). Perioperative management difficulties in parathyroidectomy for primary versus secondary and tertiary hyperparathyroidism. Maedica (Buchar), 7(2), 117–124. PMCID: PMC3557418.
  • Corneci M., Stanescu B., Trifanescu R. et al. Perioperative management difficulties in parathyroidectomy for primary versus secondary and tertiary hyperparathyroidism. Maedica (Buchar). 2012. Vol. 7 (2). P. 117–124. PMCID: PMC3557418.
  • Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2011. Vol. 6. P. 913–921. https://doi.org/10.2215/CJN.06040710.
  • Dager W. E., Kiser T. H. Systemic anticoagulation considerations in chronic kidney disease. Adv. Chronic. Kidney Dis. 2010. Vol. 17. P. 420–427. https://doi.org/10.1053/j.ackd.2010.06.002.
  • Daniel W.T., Weber C., Bailey J.A., Raggi P., Sharma J. // Surgery. – 2013. – Vol. 154(6). – P.1315-21; doi: 10.1016/j.surg.2013.06.030.
  • Davina J. T., Thomas W. L., Matthew J. T. et al. Cardiovascular effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis. Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. (4). P. 623–630. https://doi.org/10.2215/CJN.07831109.
  • Doulton Timothy W. R., Mac Gregor Graham A. Blood pressure in haemodialysis patients: The importance of the relationship between the reninangiotensin-aldosterone system, salt intake and extracellular volume. Jornal of the Renin-Angiotensin-Aldosterone System. 2004. Vol. 5. (1). P. 14–22. https://doi.org/10.3317/jraas.2004.001.
  • El-Husseini A., Wang K., Edon A. et al. Value of intraoperative parathyroid hormone assay during parathyroidectomy in dialysis and renal transplant patients with secondary and tertiary hyperparathyroidism. Nephron. 2018. Vol. 138. P. 119–128. https://doi.org/doi.org/10.1159/000482016.
  • Folsom A. R., Lutsey P. L., Astor B. C. et al. Chronic kidney diseas e and venous throm boembolism: a prospective study. Nephrol. Dial. Transplant. 2010. Vol. 25. P. 3296–3301. https://doi.org/10.1093/ndt/gfq179.
  • Frankenfield D., Roth-Yousey L., Compher. C. Comparison of predictive equations for resting metabolic rate in healthy, nonobese and obese adults: A systematic review. Journal of the American Dietetic Association. 2005. Vol. 105 (5). P. 775–789. https://doi.org/10.1016/j.jada.2005.02.005. PMID 15883556.
  • Gabrielle K. Steinl and Jennifer H. Kuo. Surgical Management of Secondary Hyperparathyroidism. Kidney Int. Rep. 2021 Feb; .Vol. 6(2). P. 254–264. https://doi.org/10.1016/j.ekir.2020.11.023.
  • Gao M.F., Yang H.L., Shi W.D. Simultaneous bilateral quadriceps tendon rupture in a patient with hyperparathyroidism undergoing long-term haemodialysis: a case report and literature review. // J. Int. Med. Res. – 2013. – Vol.41(4). – P. 1378-83. doi: 10.1177/0300060513490616.
  • Giuseppe Mancia et al. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013. Vol. 34 (Issue 28). P. 2159 –2219. https://doi.org/10.1093/eurheartj/eht151
  • Gomes E. M., Nunes R. C., Lacativa P. G. et al. Ectopic and extranumerary parathyroid glands location in patients with hyperparathyroidism secondary to end stage renal disease. Acta. Cir. Bras. 2007. Vol. 22. P. 105–109. https://doi.org/10.1590/s0102-86502007000200005.
  • Gong L., Tang W., Lu J., Xu W. Thermal ablation versus parathyroidectomy for secondary hyperparathyroidism: a metaanalysis. Int. J. Surg. 2019. Vol. 70. P. 13–18. https://doi.org/10.1016/j.ijsu.2019.08.004.
  • Guillaume J., Jean-Claude, Thierry V. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrol. Dial. Transplant. –2009. – Vol. 24, no. 9. – Р. 2792–279. – doi: 10.1093/ndt/gfp191.
  • Herzog C. A., Asinger R. W., Berger A. K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes ( KDIGO ). Kidney Int. 2011. Vol. 80 (6). P. 572–86. https://doi.org/10.1038/ki.2011.223.
  • Hiramitsu T., Tomosugi T., Okada M. et al. Pre-operative localisation of the parathyroid glands in secondary hyperparathyroidism: a retrospective cohort study. Sci. Rep. 2019. Vol. 9. P. 14634. https://doi.org/10.1038/s41598-019-51265-y.
  • Huskisson E. C. Measurement of pain. Lancet. 1974. Nov. Vol. 9 (2). P. 1127–1131. https:// doi: 10.1016/s0140-6736(74)90884-8.
  • Huskisson E. C. (1974). Measurement of pain. Lancet, Nov., 9, (2), 1127–1131. https:// doi: 10.1016/s0140-6736(74)90884-8.
  • Isakova T., Wahl P., Vargas G. S., Gutiйrrez O. M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease // Kidney Int. – 2011. – Vol. 79, no. 12. – P. 1370–1378. – doi: 10.1038/ki.2011.47.
  • Jalal D. I., Chonchol M., Targher G. Disorders of hemostasis as sociated with chronic kidney disease. Semin. Thromb. Hemost. 2010. Vol. 36 (1). P. 34–40. https://doi.org/10.1055/s-0030-1248722.
  • Ketteler M., Block G. A, Evenepoel P. et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann. Intern. Med. 2018. Vol. 168 (6). P. 422–430. https://doi.org/ 10.7326/M17-2640.
  • Kim S. M., Long J., Montez-Rath M. E., Leonard M. B., Norton J. A., Chertow G. M. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin. J. Am. Soc. Nephrol. 2016. Vol. 11. P. 1260–1267. https://doi.org/10.2215%2FCJN.10370915.
  • Lau W. L., Obi Y., Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 2018. Vol. 13. P. 952–961. https://doi.org/10.2215/CJN.10390917.
  • Lee Y.T., Ng H.Y., Kuo C.C., Chen T.C., Wu C.S., Chiu T.T, Lee W.C., Lee C.T. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patient // Nutrients. – 2013. – Vol. 95(4). – P.1336-48. doi: 10.3390/nu5041336.
  • Levin A., Bakris G. L., Molitch M. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007. Vol. 71. P. 31–38. https://doi.org/10.1038/sj.ki.5002009.
  • Mads Siggaard–Andersen & Ole Siggaard-Andersen. Oxygen status algorithm, version 3, with some applications. Acta Anaesthesiologica Scand. 1995. Vol.39. Supplementum. № 107. P. 13-20. https://doi.org/10.1111/j.1399-6576.1995.tb04324.x.
  • Menon C. M., Ix J. H. Dietary phosphorus, serum phosphorus, and cardiovascular disease // Ann. N.Y. Acad. Sci. – 2013. – Vol. 1371. – doi: 10.1111/nyas.12283.
  • Merry A., Cooper J., Soyannwo O., et al. (2010). International Standards for a Safe Practice of Anesthesia 2010. Can. J. Anaesth., 57, (11), 1027–1034. https://doi.org/10.1007/s12630-010-9381-6.
  • Merry A., Cooper J., Soyannwo O., et al. International Standards for a Safe Practice of Anesthesia 2010. Can. J. Anaesth., 57, (11), 1027–1034. https://doi.org/10.1007/s12630-010-9381-6.
  • Miccoli P. Intraoperative parathyroid hormone assay during surgery for secondary hyperparathyroidism: is it time to give up the chase at the hormone? Endocrine. 2012. Vol. 42. P. 459–460. https://doi.org/10.1007/s12020-012-9724-x.
  • Morse S. A., Dang A., Thakur V., Shang R., Reisin E. Hypertension in Chronic Dialysis Patients: Pathophysiology, Monitoring, and Treatment. Am. J. Med. Sciences. 2003. Vol. 325 (Issue 4). – P. 194 –201. https://doi.org/10.1097/00000441-200304000-00005.
  • National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003. Vol. 42 (suppl 3). S1–S201. PMID: 14520607.
  • Ohe M.N., Santos R.O., Kunii I.S., Carvalho A.B., Abrahão M., Neves M.C., Lazaretti-Castro M., Cervantes O., Vieira J.G. Intraoperative PTH cutoff definition to predict successful parathyroidectomy in secondary and tertiary hyperparathyroidism // Braz. J Otorhinolaryngol. – 2013 - Vol. 79(4). –P. 494-9. doi: 10.5935/1808-8694.20130088.
  • Ohtake T., Kobayashi S., Moriya H., et al. High Prevalence of Occult Coronary Artery Stenosis in Patients with Chronic Kidney Disease at the Initiation of Renal Replacement Therapy: An Angiographic Examination. J. Am. Soc. Nephrol. 2005. Vol. 16. P. 1141–1148. https//doi.org/10.1681/ASN.2004090765.
  • Oliveira R. B., Cancela A. L., Graciolli F. G. et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? // Clin. J. Am. Soc. Nephrol. – 2010. – Vol. 5, no. 2. – P. 286–291. – doi: 10.2215/CJN.05420709.
  • Parfrey P. S., Chertow G. M., Block G. A. et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J. Clin. Endocrinol. Metab. 2013. Vol. 98. P. 4834–4844. https://doi.org/10.1210/jc.2013-2975.
  • Ramos A. M., Albalate M., Vázquez S., Caramelo C., Egido J., Ortiz A. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int. Suppl. 2008. Vol. 74. Suppl 111. S88–S93. https://doi.org/10.1038/ki.2008.543.
  • Rao N., Crail S. Images in clinical medicine. Metastatic calcification and long-term hemodialysis // N. Engl. J. Med. – 2013. – Vol. 368(25). – P.2415. doi: 10.1056/NEJMicm1202544.
  • Shlipak M. G., Fried L. F., Crump C. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003. Vol. 107. P. 87–92. https://doi.org/10.1161/01.cir.0000042700.48769.59.
  • Siggaard-Andersen O., Gøthgen I. H., Wimberley P. D., Fogh-Andersen N. The oxygen status of the arterial blood reviser; relevant oxygen parameters for monitoring the arterial oxygen availability. Scand. J. Clin. Lab. Invest. 1990. №50. Suppl. 203. P. 17-28. https://doi.org/10.3109/00365519009087488.
  • Sumida K., Nakamura M., Ubara Y., Marui Y., Tanaka K., Takaichi K., Tomikawa S., Inoshita N., Ohashi K. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients // Am. J. Nephrol. – 2013. – Vol. 37(5). – P. 405-12. doi: 10.1159/000350211.
  • Tay K. H., Lip G. Y. What «drives» the link between the renin-angiotensin- aldosterone system and the prothrombotic state in hypertension? Am. J. Hypertens. 2008. Vol. 21. P. 1278–1279. https://doi.org /10.1038/ajh.2008.315.
  • Tomiyama C., Carvalho A. B., Higa A., Jorgetti V., Draibe S. A., Canziani M. E. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J. Bone Miner. Res. 2010. Vol. 25. P. 499–504. https://doi.org/10.1359/jbmr.090735.
  • Udelsman R., Lin Z., Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann. Surg. 2011. Vol. 253. P. 585–591. https://doi.org/10.1097/SLA.0b013e318208fed9.
  • Udomkarnjananun S., Kongnatthasate K., Praditpornsilpa K., Eiam-Ong S., Jaber B. L., Susantitaphong P. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2019. Vol. 4. P. 231–244. https://doi.org/10.1016/j.ekir.2018.10.002.
  • van der Plas W. Y., Noltes M. E., van Ginhoven T. M., Kruijff S. Secondary and tertiary hyperparathyroidism: a narrative review. Scand. J Surg. 2019. Vol. 109 (4). P. 271-278. https://doi.org/10.1177/1457496919866015.
  • Vincent M. Brandenburg and Jürgen Floege. Adynamic bone disease—bone and beyond. NDT Plus. 2008. Vol. 1 (3). P. 135–147. htts://doi.org/10.1093/ndtplus/sfn040.
  • Vulpio C., Bossola M., Di Stasio E. et al. Intra-operative parathyroid hormone monitoring through central laboratory is accurate in renal secondary hyperparathyroidism. Clin. Biochem. 2016. Vol. 49. P. 538–543. https://doi.org/10.1016/j.clinbiochem.2016.01.012.
  • Walter S., Baruch A., Dong J., Tomlinson J.E., Alexander S.T., Janes J., Hunter T., Yin Q., Maclean D., Bell G., Mendel D.B., Johnson R.M., Karim F. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients // J. Pharmacol. Exp. Ther. – 2013. – Vol. 346(2). - P. 229-40. doi: 10.1124/jpet.113.204834.
  • Wattanakit K., Cushman M., Stehman Breen C. et al. Chronic kidney disease in creases risk for venous thromboembolism. J. Am. Soc. Nephrol. 2008. Vol. (1) 19. P. 135–140. https://doi.org 10.1681/ASN.2007030308.
  • William H. Geerts, David Bergqvist, Graham F. Pineo, John A. Heit, Charles M. Samama, Michael R. Lassen and Clifford W. Colwell. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008. Vol. 133.P. 3815-4535. https://doi.org/10.1378/chest.08-0656.
  • Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease // Kidney Іnt. – 2012. – Vol. 82, no. 7. –P. З737–747. – doi: 10.1038/ki.2012.176.
  • Yang J., Hao R., Yuan L., Li C., Yan J., Zhen L. Value of dual-phase (99m)Tc-sestamibi scintigraphy with neck and thoracic SPECT/CT in secondary hyperparathyroidism // AJR Am. J Roentgenol. – 2014. - Vol. 202(1). – P. 180-84. doi: 10.2214/AJR.13.11053.
  • Zhang Y, Lu Y., Feng S., Zhan Z, Shen H. Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Renal Fail. 2019. Vol. 41. P. 921–929. https://doi.org/10.1080/0886022X.2019.1666724.